SOAR 2016-18:越南、柬埔寨、新加坡和菲律宾抗生素耐药性调查结果
该研究测定了2016-18年四个亚洲国家社区获得性呼吸道感染分离的260株肺炎链球菌和258株流感嗜血杆菌的MIC,并用CLSI、EUCAST(剂量特异性)和PK/PD折点评估敏感性。结果显示各国及菌种间敏感性差异大,越南分离株敏感性最低;不同EUCAST剂量折点首次量化了提高剂量对敏感性的影响。
要点
- 越南肺炎链球菌对多数药物敏感性低,仅氟喹诺酮类CLSI敏感率>90%。
- 越南流感嗜血杆菌仅对阿莫西林/克拉维酸、头孢曲松和大环内酯类敏感率>85%。
- 应用EUCAST剂量特异性折点可量化提高剂量对敏感性的影响。
核心结论
- 抗生素敏感性因国家和菌种而异,越南分离株敏感性最低。
- 了解耐药模式有助于临床医生选择社区获得性呼吸道感染的经验性治疗方案。
研究设计与样本
- 研究测定了2016-18年越南、柬埔寨、新加坡和菲律宾社区获得性呼吸道感染分离的260株肺炎链球菌和258株流感嗜血杆菌的MIC。
- 采用CLSI肉汤微量稀释法测定MIC,并使用CLSI、EUCAST(剂量特异性)和PK/PD折点评估敏感性。
主要发现
- 越南肺炎链球菌(n=161)敏感性最低,CLSI折点下氟喹诺酮类敏感率>90%,阿莫西林、阿莫西林/克拉维酸和头孢曲松约60%,其他多数药物<14%。
- 柬埔寨(n=48)和新加坡(n=34)肺炎链球菌对甲氧苄啶/磺胺甲噁唑和口服青霉素敏感率约30%,对氟喹诺酮类达100%。
- 柬埔寨(n=30)、菲律宾(n=59)和新加坡(n=80)流感嗜血杆菌对阿莫西林/克拉维酸、头孢菌素类(新加坡头孢克洛77.5%除外)、大环内酯类和氟喹诺酮类CLSI敏感率>90%。
- 越南流感嗜血杆菌(n=89)仅对阿莫西林/克拉维酸(95.5%)、头孢曲松(100%)和大环内酯类(87.6%-89.9%)敏感率>85%,对其他抗生素敏感性范围为7.9%(甲氧苄啶/磺胺甲噁唑)至57.3%-59.6%(氟喹诺酮类)和70.8%(头孢克肟)。
- 应用EUCAST低剂量和高剂量折点(阿莫西林、阿莫西林/克拉维酸、氨苄西林、青霉素、头孢曲松、克拉霉素、红霉素、左氧氟沙星和甲氧苄啶/磺胺甲噁唑)首次在SOAR研究中量化了提高剂量对敏感性的影响。
关键数值与推荐
- 越南肺炎链球菌:氟喹诺酮类CLSI敏感率>90%,阿莫西林、阿莫西林/克拉维酸和头孢曲松约60%,其他多数药物<14%。
- 柬埔寨和新加坡肺炎链球菌:甲氧苄啶/磺胺甲噁唑和口服青霉素敏感率约30%,氟喹诺酮类100%。
- 柬埔寨、菲律宾和新加坡流感嗜血杆菌:阿莫西林/克拉维酸、头孢菌素类(新加坡头孢克洛77.5%)、大环内酯类和氟喹诺酮类CLSI敏感率>90%。
- 越南流感嗜血杆菌:阿莫西林/克拉维酸95.5%、头孢曲松100%、大环内酯类87.6%-89.9%;其他药物敏感性7.9%-70.8%。
临床怎么用
- 临床医生在选择社区获得性呼吸道感染经验性治疗时,应考虑国家间和菌种间的耐药差异。
- 在越南等高耐药地区,经验性治疗应优先选择敏感性高的药物如氟喹诺酮类(针对肺炎链球菌)或阿莫西林/克拉维酸、头孢曲松(针对流感嗜血杆菌)。
- EUCAST剂量特异性折点可帮助评估提高抗生素剂量对敏感性的潜在获益。
局限性
- 样本量小,且每个国家仅一或两个中心参与。
- 部分参与国家耐药数据稀缺,但任何抗生素敏感性信息仍有价值。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: To determine antibiotic susceptibility of Streptococcus pneumoniae and Haemophilus influenzae isolates collected from community-acquired respiratory tract infections (CA-RTIs) in 2016-18 in four Asian countries. METHODS: MICs were determined by CLSI broth microdilution and susceptibility was assessed using CLSI, EUCAST (dose-specific) and pharmacokinetic/pharmacodynamic (PK/PD) breakpoints. RESULTS: In total, 260 S. pneumoniae and 258 H. influenzae isolates were tested. Pneumococci from Vietnam (n = 161) were the least susceptible, with rates of susceptibility >90% for fluoroquinolones by CLSI breakpoints, ∼60% for amoxicillin, amoxicillin/clavulanic acid and ceftriaxone but <14% for most other agents. Pneumococcal isolates from Cambodia (n = 48) and Singapore (n = 34) showed susceptibilities ranging from ∼30% for trimethoprim/sulfamethoxazole and oral penicillin to 100% for fluoroquinolones. Among isolates of H. influenzae from Cambodia (n = 30), the Philippines (n = 59) and Singapore (n = 80), rates of susceptibility using CLSI breakpoints were >90% for amoxicillin/clavulanic acid, cephalosporins [except cefaclor in Singapore (77.5%)], macrolides and fluoroquinolones; for isolates from Vietnam (n = 89) the rates of susceptibility were >85% only for amoxicillin/clavulanic acid (95.5%), ceftriaxone (100%) and macrolides (87.6%-89.9%). Susceptibility to other antibiotics ranged from 7.9% (trimethoprim/sulfamethoxazole) to 57.3%-59.6% (fluoroquinolones) and 70.8% (cefixime). The application of different EUCAST breakpoints for low and higher doses for some of the antibiotics (amoxicillin, amoxicillin/clavulanic acid, ampicillin, penicillin, ceftriaxone, clarithromycin, erythromycin, levofloxacin and trimethoprim/sulfamethoxazole) allowed, for the first time in a SOAR study, the effect of raising the dosage on susceptibility to be quantified. A limitation of the study was the small sample sizes and only one or two sites participating per country; however, since susceptibility data are scarce in some of the participating countries any information concerning antibiotic susceptibility is of value. CONCLUSIONS: Antibiotic susceptibility varied across countries and species, with isolates from Vietnam demonstrating the lowest susceptibility. Knowledge of resistance patterns can be helpful for clinicians when choosing empirical therapy options for CA-RTIs.
引用
- Torumkuney D, Van PH, Thinh LQ, et al. Results from the Survey of Antibiotic Resistance (SOAR) 2016-18 in Vietnam, Cambodia, Singapore and the Philippines: data based on CLSI, EUCAST (dose-specific) and pharmacokinetic/pharmacodynamic (PK/PD) breakpoints. J Antimicrob Chemother. 2020. PMID: 32337597. doi:10.1093/jac/dkaa082
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。